Group 1 - The core point of the article is that Lianhua Technology (002250) announced that neither the company nor its controlling subsidiaries have experienced overdue guarantees, litigation-related guarantees, or losses due to being judged against in guarantees [1] Group 2 - The announcement reflects the company's stable financial position and risk management practices [1] - The absence of litigation and guarantee-related losses indicates a lower risk profile for investors [1] - This information may enhance investor confidence in Lianhua Technology's operational integrity [1]

Group 1: Gold and Silver Market Outlook - A Reuters survey indicates that gold prices are expected to reach a new high of $4,746.50 per ounce by 2026, driven by geopolitical uncertainties and strong central bank purchases, marking a significant increase from last year's forecast of $4,275 [1] - The average price expectation for silver in 2026 has also been raised to $79.50 per ounce, up from $50 in the previous year's survey [1] Group 2: Currency and Economic Analysis - The strong US dollar is exerting downward pressure on gold and silver prices, with analysts suggesting that if the dollar's rebound continues, it may further impact gold prices negatively [2] - UBS forecasts a 10% increase in global stock markets by the end of the year, with a focus on diversification into markets like China, Japan, and Europe, driven by strategic autonomy and fiscal expansion [3] - Mitsubishi UFJ reports that the Japanese yen has fallen to a near two-week low due to election expectations, with potential for continued selling pressure as confidence in the ruling party's stability grows [4] - Goldman Sachs warns of upward fiscal risks in Japan ahead of the upcoming elections, suggesting that unless the Bank of Japan accelerates interest rate hikes, the yen may weaken further [6] Group 3: Sector-Specific Insights - Zhongtai Securities expresses a positive outlook on the raw material pharmaceutical sector, highlighting innovations in small nucleic acids and ADC toxins as catalysts for growth [7] - CITIC Securities recommends focusing on automotive companies with strong cost transfer capabilities and global layouts, as rising raw material prices are expected to pressure profit margins in the first quarter of 2026 [8] - Galaxy Securities identifies two main paths for AI-driven benefits: enhancing platform efficiency and improving production efficiency through content and tools, suggesting a focus on internet stocks and AI-related applications [9]

证券代码：002250 证券简称：联化科技 公告编号：2026-003 联化科技股份有限公司 关于公司为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、对外担保情况概述 联化科技股份有限公司（以下简称"公司"、"联化科技"）分别于2025年10 月9日召开了第九届董事会第二次会议和2025年10月28日召开了2025年第二次临 时股东会，审议通过了《关于公司为子公司提供担保额度预计的议案》，同意为 公司为子公司新增担保额度70,000万元，其中为最近一期资产负债率低于70%的 控股子公司新增担保额度不超过50,000万元，为最近一期资产负债率高于70%的 控股子公司新增担保额度不超过等值人民币20,000万元。关于担保额度的情况， 具体详见公司刊登于《证券时报》《上海证券报》和巨潮资讯网（www.cninfo.com.cn） 的《关于公司为子公司提供担保额度预计的公告》（公告编号：2025-047）。 二、担保进展情况 公司与中国农业银行股份有限公司台州黄岩支行于2026年2月5日签署了编 号为33100620260005611和 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [9]. Core Insights - The company is positioned as a leading provider of chemical technology solutions, focusing on agricultural CDMO, pharmaceutical small molecules, and small nucleic acid CDMO, with significant achievements in functional chemicals [3][5]. - The agricultural sector is experiencing steady growth, while the pharmaceutical CDMO sector shows promising prospects, particularly in small nucleic acids, which are gaining traction in the market [6][7]. - The company is expanding its footprint in the new energy sector, particularly in lithium battery materials, which presents substantial growth potential [8]. Summary by Relevant Sections Company Overview - Founded in 1985 and located in Taizhou, Zhejiang Province, the company has evolved from producing flavor and fragrance intermediates to becoming a global custom manufacturing service provider in agriculture, pharmaceuticals, and functional chemicals [5][19]. - The company has established a comprehensive business platform that meets diverse customer needs across various stages of product development and lifecycle [21][24]. Agricultural Sector - The global agricultural industry is entering a mature phase, with projected sales of $77.2 billion in 2024, reflecting a 6.8% year-over-year decline. However, the sector is expected to expand steadily due to ongoing population growth [6][53]. - The competitive landscape is characterized by oligopolistic structures, with the top five companies holding a 57.4% market share in 2024, driven by innovation and strong brand channels [6][53]. Pharmaceutical CDMO - The company has been involved in small molecule CDMO for over a decade, with a robust revenue growth trajectory since 2017. A significant rebound is expected in 2025, with projected revenue of 1.018 billion yuan, a 42.8% increase year-over-year [7]. - The company is expanding into the small nucleic acid drug market, which is projected to see 32 transactions worth $29.022 billion in 2025, highlighting the growing commercial value of this segment [7]. Functional Chemicals - The lithium-ion battery electrolyte market is rapidly growing, with expected shipments reaching 2.235 million tons by 2025, a 46.4% increase. The company is focusing on lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide as key products in this sector [8][24]. - The company is well-positioned to capitalize on the increasing demand for lithium battery materials, with a focus on developing high-performance products [8]. Financial Performance - The company is expected to achieve net profits of 410 million, 630 million, and 790 million yuan for the years 2025 to 2027, respectively, indicating strong financial growth prospects [9].

Investment Rating - The report assigns a "Buy" rating for the company, marking the first coverage of the stock [1]. Core Insights - The company, Zhejiang Jinhua New Material Co., Ltd., is a leading supplier of ketoxime products, focusing on the research, production, and sales of fine chemical products, particularly silane crosslinkers and hydroxylamine salts [9][14]. - The hydroxylamine salt market is expanding, driven by increased demand in downstream industries such as agriculture, pharmaceuticals, and environmental applications [40][44]. - The company has established a green circular industrial chain, showcasing its commitment to sustainable practices and innovation in production processes [16][57]. Summary by Sections 1. Company Overview - Zhejiang Jinhua New Material Co., Ltd. specializes in ketoxime series fine chemicals and has received numerous accolades, including being recognized as a national "little giant" enterprise [14]. - The company has developed a unique green circular industrial chain for ketoxime products, enhancing its competitive edge [16]. 2. Market Dynamics - The fine chemical industry is a strategic focus in China's chemical sector, with hydroxylamine salts experiencing stable market growth due to their applications in various high-demand sectors [39][40]. - The global hydroxylamine salt market is projected to grow from 2.714 billion yuan in 2023 to 3.179 billion yuan by 2028, with a CAGR of 3.21% [40][41]. 3. Financial Performance - The company forecasts revenues of 1.064 billion yuan in 2025, with a projected net profit of 198.77 million yuan, reflecting a slight decline from the previous year [1]. - The earnings per share (EPS) is expected to be 1.47 yuan in 2025, with a P/E ratio of 34.00 [1]. 4. Competitive Position - The company has established itself as a market leader in silane crosslinkers and hydroxylamine salts, with significant market shares of 38.16% and 42.37% respectively by 2024 [57][58]. - It has built a robust customer base, including major international and domestic companies, ensuring stable demand for its products [60]. 5. Technological Innovation - The company has developed high-purity electronic-grade hydroxylamine water solution, breaking the monopoly of foreign firms and filling a gap in the domestic market [61]. - It has a strong focus on R&D, with several patents granted for its innovative production processes, ensuring product quality and environmental sustainability [63].

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 财通证券发布研报称，化学原料药PPI长期承压，行业经历低谷。随着上游成本上涨、政策驱动出清， 以及GLP-1口服小分子、小核酸等新药产业化趋势成熟，头部原料药企业凭借卡位MNC供应链的核心优 势，有望从周期股转向创新产业链，开启第二增长曲线。 财通证券主要观点如下： 化学原料药PPI指数长期承压 过去几年，原料药行业经历了艰难时期。各类产品价格下跌，其中沙坦类、肝素类、动保类等价格已跌 至历史低位，部分龙头企业甚至处于亏损阶段。同时，集采对化药制剂的降价效应逐渐传递到上游原 料，而致原料药利润率不断下降。化学原料药PPI指数长期承压。 原料药企业有望开启第二增长曲线 投资建议：关注头部中间体、原料药及CDMO企业，建议关注诚达药业、联化科技、药明康德、凯莱 英、九州药业、奥锐特、天宇药业、康龙化成、博腾股份等。 风险提示：商业化不及预期的风险；贸易摩擦的风险；产能提升不及预期的风险。 原材料价格及汇率上涨，反内卷政策有望驱动原料药行业加速出清，同时，新兴产业趋势走向成熟，原 料药企业有望开启第二增长曲线。由于石油化工相关上游原料价格有上 ...

Group 1 - The core point of the article is that Lianhua Technology has received a high-tech enterprise certificate from various governmental bodies in Shandong Province, indicating its recognition as a high-tech company [2][2][2] Group 2 - The certificate is a renewal of the previous high-tech enterprise status for Lianhua Technology (Dezhou) Co., Ltd., which had reached the expiration of its prior certification [2][2][2]

格隆汇2月2日丨联化科技(002250.SZ)公布，子公司联化科技（德州）有限公司（简称"德州联化"）于近 日收到由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、国家税务总局山东省税务局联合 批准颁发的高新技术企业证书。德州联化被认定为高新技术企业（编号：GR202537001632），发证日 期为2025年12月8日，认定有效期为三年。本次系德州联化原高新技术企业证书有效期届满所进行的重 新认定。 ...

格隆汇2月2日丨联化科技(002250.SZ)公布，子公司联化科技（德州）有限公司（简称"德州联化"）于近 日收到由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、国家税务总局山东省税务局联合 批准颁发的高新技术企业证书。德州联化被认定为高新技术企业（编号：GR202537001632），发证日 期为2025年12月8日，认定有效期为三年。本次系德州联化原高新技术企业证书有效期届满所进行的重 新认定。 ...

证券代码：002250 证券简称：联化科技 公告编号：2026-002 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 二〇二六年二月三日 联化科技股份有限公司（以下简称"公司"）子公司联化科技（德州）有限 公司（以下简称"德州联化"）于近日收到由山东省科学技术厅、山东省工业和 信息化厅、山东省财政厅、国家税务总局山东省税务局联合批准颁发的高新技术 企业证书。德州联化被认定为高新技术企业（编号：GR202537001632），发证日 期为2025年12月8日，认定有效期为三年。 本次系德州联化原高新技术企业证书有效期届满所进行的重新认定。根据相 关规定，德州联化自本次通过高新技术企业重新认定后三年内（2025年至2027 年）继续享受国家关于高新技术企业的相关优惠政策，即按15%的税率缴纳企业 所得税。 鉴于德州联化2025年已暂按15%的税率预缴了企业所得税，因此，本事项不 会影响公司2025年度相关财务数据。 特此公告。 联化科技股份有限公司董事会 联化科技股份有限公司 关于子公司通过高新技术企业重新认定的公告 ...